These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1884747)

  • 1. Comparison of the bioavailability of two slow release preparations of disopyramide.
    Bogaert MG; Belpaire F; De Wilde G; Lefebvre RA
    Eur J Clin Pharmacol; 1991; 40(6):629-30. PubMed ID: 1884747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the anticholinergic effects of two formulations of disopyramide in healthy volunteers.
    Longmore J; Berry JL; Szabadi E; Bradshaw CM
    Eur J Clin Pharmacol; 1990; 39(3):305-9. PubMed ID: 2257872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative bioavailability of disopyramide after multiple dosing with standard capsules and controlled-release tablets.
    Forssell G; Graffner C; Nordlander R; Nyquist O
    Eur J Clin Pharmacol; 1980; 17(3):209-13. PubMed ID: 7363933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma concentration of disopyramide given as capsules and controlled release tablets.
    Arnman K; Graffner C; Rikner L; Ryden L; Voog L
    Eur J Clin Pharmacol; 1983; 24(2):199-203. PubMed ID: 6840167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma levels of disopyramide after administration of conventional capsules and sustained-release tablets.
    Nauta IL; van de Calseyde J; Hertzberger DP
    Curr Med Res Opin; 1983; 8(8):582-93. PubMed ID: 6653136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immediate- versus controlled-release disopyramide: importance of saturable binding.
    Davies RF; Siddoway LA; Shaw L; Barbey JT; Roden DM; Woosley RL
    Clin Pharmacol Ther; 1993 Jul; 54(1):16-22. PubMed ID: 8330460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability.
    Bryson SM; Whiting B; Lawrence JR
    Br J Clin Pharmacol; 1978 Nov; 6(5):409-19. PubMed ID: 728284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained release disopyramide compared to plain capsules after change-over from intravenous infusion.
    Lien E; Bakke OM
    Br J Clin Pharmacol; 1983 Jul; 16(1):71-6. PubMed ID: 6882625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability of total and unbound disopyramide: implications for clinical use of the immediate and controlled-release dosage forms.
    Piscitelli DA; Fischer JH; Schoen MD; Hoon TJ; Bauman JL
    J Clin Pharmacol; 1994 Aug; 34(8):823-8. PubMed ID: 7962670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of and adverse effects of disopyramide. Comparison of capsules, controlled release tablets and placebo in patients with chronic ventricular arrhythmias.
    Ekelund LG; Nilsson E; Walldius G
    Eur J Clin Pharmacol; 1986; 29(6):673-7. PubMed ID: 3519236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of neglecting nonlinear plasma-protein binding on disopyramide bioavailability studies.
    Upton RA; Williams RL
    J Pharmacokinet Biopharm; 1986 Aug; 14(4):365-79. PubMed ID: 3772738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disopyramide plasma concentrations following single and multiple doses of the immediate- and controlled-release capsules.
    Karim A; Schubert EN; Burns TS; Palmer M; Zinny MA
    Angiology; 1983 Jun; 34(6):375-92. PubMed ID: 6346960
    [No Abstract]   [Full Text] [Related]  

  • 13. Relative bioavailability of two disopyramide capsules in humans based on total, unbound, and unbound enantiomer concentrations.
    Takahashi H; Ogata H; Shimizu M; Hashimoto K; Masuhara K; Kashiwada K; Someya K
    Biopharm Drug Dispos; 1993 Jul; 14(5):409-18. PubMed ID: 8218959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion from intravenous to oral slow-release disopyramide in acute myocardial infarction.
    Zannad F; Royer-Morrot MJ; Zakari I; Sadoul N; Royer RJ
    Fundam Clin Pharmacol; 1987; 1(3):219-24. PubMed ID: 3428841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biological availability and assessment of the antiarrhythmic activity of Disocor and Disocor Retard].
    Sadowski Z; Jasiński K; Nartowicz E; Koliński P; Ochotny R; Burduk P
    Wiad Lek; 1990 Jan 1-15; 43(1-2):65-71. PubMed ID: 2368387
    [No Abstract]   [Full Text] [Related]  

  • 16. Serum drug concentrations and adverse effects in cardiac patients after administration of a new controlled-release disopyramide preparation.
    Zema MJ
    Ther Drug Monit; 1984; 6(2):192-8. PubMed ID: 6740739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of controlled-release disopyramide in patients with cardiac arrhythmias.
    Capparelli EV; DiPersio DM; Zhao H; Kluger J; Chow MS
    J Clin Pharmacol; 1988 Apr; 28(4):306-11. PubMed ID: 3392228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance therapy after i.v. administration of disopyramide with an oral sustained release preparation, a pharmacokinetic study.
    Liem KL; Hollander JM
    Br J Clin Pharmacol; 1984 Aug; 18(2):226-8. PubMed ID: 6487461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability of disopyramide in normal volunteers using unbound concentration.
    Braun J; Sörgel F; Gluth WP; Oie S
    Eur J Clin Pharmacol; 1987; 32(6):625-9. PubMed ID: 3653232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Delayed-action disopyramide in the treatment of hyperkinetic ventricular arrhythmia. A randomized clinical comparative study vs immediate-action disopyramide].
    Romanò M; Spinelli A; Cazzani E; Muzio L
    Clin Ter; 1991 Jul; 138(1):13-9. PubMed ID: 1834395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.